Restored degradation of the Alzheimer's amyloid-β peptide by targeting amyloid formation

Journal of Neurochemistry

Volumn 108, Issue 5, 2009, Pages 1198-1207

  Crouch, Peter J ^a,b   Tew, Deborah J ^a,b   Du, Tai ^a,b   Nguyen, Diem Ngoc ^a   Caragounis, Aphrodite ^a,b   Filiz, Gulay ^a,b   Blake, Rachel E ^c   Trounce, Ian A ^c   Soon, Cynthia P W ^a,b   Laughton, Katrina ^a,b   Perez, Keyla A ^a,b,d   Li, Qiao Xin ^a,b   Cherny, Robert A ^b   Masters, Colin L ^b   Barnham, Kevin J ^a,b,d   White, Anthony R ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^c St Vincent's Health ^*  (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Alzheimer's disease; Amyloid ; Oligomer; Proteolysis; Therapeutic; Zinc

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; CLIOQUINOL; GELATINASE A; INSULINASE; MEMBRANE METALLOENDOPEPTIDASE; ZINC;

ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; ENZYME ACTIVITY; HYDROPHOBICITY; MASS SPECTROMETRY; MOUSE; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION;

AMYLOID; AMYLOID BETA-PROTEIN; CLIOQUINOL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLUTAMIC ACID; GLUTAMINE; HUMANS; INSULYSIN; MATRIX METALLOPROTEINASE 2; MICROSCOPY, ELECTRON, TRANSMISSION; MUTATION; NEPRILYSIN; PEPTIDE FRAGMENTS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TIME FACTORS; ZINC;

EID: 59449101792     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2009.05870.x     Document Type: Article

References (58)

1. Adlard P. A., Cherny R. A., Finkelstein D. I. et al. (2008) Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Aβ. Neuron 59, 43 55.
2. Atwood C. S., Moir R. D., Huang X., Scarpa R. C., Bacarra N. M. E., Romano D. M., Hartshorn M. A., Tanzi R. E. Bush A. I. (1998) Dramatic aggregation of Alzheimer Aβ by Cu(II) is induced by conditions representing physiological acidosis. J. Biol. Chem. 273, 12817 12826.
3. Backstrom J. R., Lim G. P., Cullen M. J. Tokes Z. A. (1996) Matrix metalloproteinase-9 (MMP-9) is synthesized in neurons of the human hippocampus and is capable of degrading the amyloid-β peptide (1-40). J. Neurosci. 16, 7910 7919.
4. Barnham K. J., Ciccotosto G. D., Tickler A. K. et al. (2003) Neurotoxic, redox-competent Alzheimer's β-amyloid is released from lipid membrane by methionine oxidation. J. Biol. Chem. 278, 42959 42965.
5. Bateman R. J., Munsell L. Y., Morris J. C., Swarm R., Yarasheski K. E. Holtzman D. M. (2006) Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat. Med. 12, 856 861.
6. Bush A. I. (2003) The metallobiology of Alzheimer's disease. Trends Neurosci. 26, 207 214.
7. Bush A. I., Pettingall W. H., Multhaup G., Paradis M., Vonsattel J.-P., Gusella J. F., Beyreuther K., Masters C. L. Tanzi R. E. (1994) Rapid induction of Alzheimer Aβ amyloid formation by zinc. Science 265, 1464 1467.
8. Carson J. A. Turner A. J. (2002) Beta-amyloid catabolism: roles for neprilysin (NEP) and other metallopeptidases? J. Neurochem. 81, 1 8.
9. Chartier-Harlin M. C., Crawford F., Houlden H. et al. (1991) Early-onset Alzheimer's disease caused by mutations at codon 717 of the β-amyloid precursor protein gene. Nature 353, 844 846.
10. Cherny R. A., Legg J. T., McLean C. A. et al. (1999) Aqueous dissolution of Alzheimer's disease Aβ amyloid deposits by biometal depletion. J. Biol. Chem. 274, 23223 23228.
11. Cherny R. A., Atwood C. S., Xilinas M. E. et al. (2001) Treatment with a copper-zinc chelator markedly and rapidly inhibits β-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 30, 665 676.
12. Ciccotosto G. D., Tew D., Curtain C. C. et al. (2004) Enhanced toxicity and cellular binding of a modified amyloid β peptide with a methionine to valine substitution. J. Biol. Chem. 279, 42528 42534.
13. Citron M., Oltersdorf T., Haass C., McConlogue L., Hung A. Y., Seubert P., Vigo-Pelfrey C., Lieberburg I. Selkoe D. J. (1992) Mutation of the β-amyloid precursor protein in familial Alzheimer's disease increases β-protein production. Nature 360, 672 674.
14. 1-42. J. Neurosci. 25, 672 679.
15. Crouch P. J., White A. R. Bush A. I. (2007) The modulation of metal bio-availability as a therapeutic strategy for the treatment of Alzheimer's disease. FEBS J. 274, 3775 3783.
16. Crouch P. J., Harding S. M., White A. R., Camakaris J., Bush A. I. Masters C. L. (2008) Mechanisms of Aβ mediated neurodegeneration in Alzheimer's disease. Int. J. Biochem. Cell Biol. 40, 181 198.
17. Eckman E. A. Eckman C. B. (2005) Aβ-degrading enzymes: modulators of Alzheimer's disease pathogenesis and targets for therapeutic intervention. Biochem. Soc. Trans. 33, 1101 1105.
18. El-Amouri S. S., Zhu H., Yu J., Marr R., Verma I. M. Kindy M. S. (2008) Neprilysin: an enzyme candidate to slow the progression of Alzheimer's disease. Am. J. Pathol. 172, 1342 1354.
19. Farris W., Schutz S. G., Cirrito J. R. et al. (2007) Loss of neprilysin function promotes amyloid plaque formation and causes cerebral amyloid angiopathy. Am. J. Pathol. 171, 241 251.
20. Fukami S., Watanabe K., Iwata N. et al. (2002) Aβ-degrading endopeptidase, neprilysin, in mouse brain: synaptic and axonal localization inversely correlating with Aβ pathology. Neurosci. Res. 43, 39 56.
21. Games D., Adams D., Alessandrini R. et al. (1995) Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature 373, 523 527.
22. Glenner G. G. Wong C. W. (1984a) Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. Biochem. Biophys. Res. Commun. 122, 1131 1135.
23. Glenner G. G. Wong C. W. (1984b) Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 120, 885 890.
24. Goate A., Chartier-Harlin M. C., Mullan M. et al. (1991) Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349, 704 706.
25. Hellstrom-Lindahl E., Ravid R. Nordberg A. (2008) Age-dependent decline of neprilysin in Alzheimer's disease and normal brain: inverse correlation with Aβ levels. Neurobiol. Aging 29, 210 221.
26. Hemming M. L., Patterson M., Reske-Nielsen C., Lin L., Isacson O. Selkoe D. J. (2007) Reducing amyloid plaque burden via ex vivo gene delivery of an Aβ-degrading protease: a novel therapeutic approach to Alzheimer disease. PLoS Med. 4, e262.
27. Huang X., Atwood C. S., Moir R. D., Hartshorn M. A., Vonsattel J. P., Tanzi R. E. Bush A. I. (1997) Zinc-induced Alzheimer's Aβ1-40 aggregation is mediated by conformational factors. J. Biol. Chem. 272, 26464 26470.
28. Ida N., Hartmann T., Pantel J., Schroder J., Zerfass R., Forstl H., Sandbrink R., Masters C. L. Beyreuther K. (1996) Analysis of heterogeneous βA4 peptides in human cerebrospinal fluid and blood by a newly developed sensitive western blot assay. J. Biol. Chem. 271, 22908 22914.
29. Jankowsky J. L., Slunt H. H., Ratovitski T., Jenkins N. A., Copeland N. G. Borchelt D. R. (2001) Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol. Eng. 17, 157 165.
30. Jiang Q., Lee C. Y., Mandrekar S. et al. (2008) ApoE promotes the proteolytic degradation of Aβ. Neuron 58, 681 693.
31. Kim M., Hersh L. B., Leissring M. A. et al. (2007) Decreased catalytic activity of the insulin-degrading enzyme in chromosome 10-linked Alzheimer disease families. J. Biol. Chem. 282, 7825 7832.
32. Lee J. Y., Cole T. B., Palmiter R. D., Suh S. W. Koh J. Y. (2002) Contribution by synaptic zinc to the gender-disparate plaque formation in human Swedish mutant APP transgenic mice. Proc. Natl Acad. Sci. USA 99, 7705 7710.
33. Lovell M. A., Robertson J. D., Teesdale W. J., Campbell J. L. Markesbery W. R. (1998) Copper, iron and zinc in Alzheimer's disease senile plaques. J. Neurol. Sci. 158, 47 52.
34. Marr R. A., Rockenstein E., Mukherjee A., Kindy M. S., Hersh L. B., Gage F. H., Verma I. M. Masliah E. (2003) Neprilysin gene transfer reduces human amyloid pathology in transgenic mice. J. Neurosci. 23, 1992 1996.
35. Marr R. A., Guan H., Rockenstein E., Kindy M., Gage F. H., Verma I., Masliah E. Hersh L. B. (2004) Neprilysin regulates amyloid β peptide levels. J. Mol. Neurosci. 22, 5 11.
36. Masters C. L. Beyreuther K. (2006) Alzheimer's centennial legacy: prospects for rational therapeutic intervention targeting the Aβ amyloid pathway. Brain 129, 2823 2839.
37. Masters C. L., Simms G., Weinman N. A., Multhaup G., McDonald B. L. Beyreuther K. (1985) Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc. Natl Acad. Sci. USA 82, 4245 4249.
38. Miller L. M., Wang Q., Telivala T. P., Smith R. J., Lanzirotti A. Miklossy J. (2006) Synchrotron-based infrared and X-ray imaging shows focalized accumulation of Cu and Zn co-localized with β-amyloid deposits in Alzheimer's disease. J. Struct. Biol. 155, 30 37.
39. Miners J. S., Van Helmond Z., Chalmers K., Wilcock G., Love S. Kehoe P. G. (2006) Decreased expression and activity of neprilysin in Alzheimer disease are associated with cerebral amyloid angiopathy. J. Neuropathol. Exp. Neurol. 65, 1012 1021.
40. Murakami K., Irie K., Morimoto A., Ohigashi H., Shindo M., Nagao M., Shimizu T. Shirasawa T. (2003) Neurotoxicity and physicochemical properties of Aβ mutant peptides from cerebral amyloid angiopathy: implication for the pathogenesis of cerebral amyloid angiopathy and Alzheimer's disease. J. Biol. Chem. 278, 46179 46187.
41. Nalivaeva N. N., Fisk L. R., Belyaev N. D. Turner A. J. (2008) Amyloid-degrading enzymes as therapeutic targets in Alzheimer's disease. Curr. Alzheimer Res. 5, 212 224.
42. 2+-sensitive peptides. Chembiochem 9, 531 536.
43. Roher A. E., Kasunic T. C., Woods A. S., Cotter R. J., Ball M. J. Fridman R. (1994) Proteolysis of Aβ peptide from Alzheimer disease brain by gelatinase A. Biochem. Biophys. Res. Commun. 205, 1755 1761.
44. Selkoe D. J., Abraham C. R., Podlisny M. B. Duffy L. K. (1986) Isolation of low-molecular-weight proteins from amyloid plaque fibers in Alzheimer's disease. J. Neurochem. 46, 1820 1834.
45. Sherrington R., Rogaev E. I., Liang Y. et al. (1995) Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 375, 754 760.
46. Shinkai Y., Yoshimura M., Morishima-Kawashima M., Ito Y., Shimada H., Yanagisawa K. Ihara Y. (1997) Amyloid beta-protein deposition in the leptomeninges and cerebral cortex. Ann. Neurol. 42, 899 908.
47. Smith D. P., Smith D. G., Curtain C. C. et al. (2006) Copper mediated amyloid-β toxicity is associated with an intermolecular histidine bridge. J. Biol. Chem. 281, 15145 15154.
48. 2+ induced aggregation and dityrosine formation of the Alzheimer's disease amyloid-β peptide. Biochemistry 46, 2881 2891.
49. Soto C. Castano E. M. (1996) The conformation of Alzheimer's β peptide determines the rate of amyloid formation and its resistance to proteolysis. Biochem. J. 314, 701 707.
50. Suzuki N., Cheung T. T., Cai X. D., Odaka A., Otvos L. Jr., Eckman C., Golde T. E. Younkin S. G. (1994) An increased percentage of long amyloid β protein secreted by familial amyloid β protein precursor (β APP717) mutants. Science 264, 1336 1340.
51. Syme C. D., Nadal R. C., Rigby S. E. Viles J. H. (2004) Copper binding to the amyloid-β (Aβ) peptide associated with Alzheimer's disease. Folding, coordination geometry, pH dependence, stoichiometry, and affinity of Aβ-(1-28): Insights from a range of complementary spectroscopic techniques. J. Biol. Chem. 279, 18169 18177.
52. White A. R., Du T., Laughton K. M. et al. (2006) Degradation of the Alzheimer disease amyloid β-peptide by metal-dependent up-regulation of metalloprotease activity. J. Biol. Chem. 281, 17670 17680.
53. Yan P., Hu X., Song H. et al. (2006) Matrix metalloproteinase-9 degrades amyloid-β fibrils in vitro and compact plaques in situ. J. Biol. Chem. 281, 24566 24574.
54. Yang D. S., McLaurin J., Qin K., Westaway D. Fraser P. E. (2000) Examining the zinc binding site of the amyloid-β peptide. Eur. J. Biochem. 267, 6692 6698.
55. Yasojima K., Akiyama H., McGeer E. G. McGeer P. L. (2001a) Reduced neprilysin in high plaque areas of Alzheimer brain: a possible relationship to deficient degradation of β-amyloid peptide. Neurosci. Lett. 297, 97 100.
56. Yasojima K., McGeer E. G. McGeer P. L. (2001b) Relationship between β amyloid peptide generating molecules and neprilysin in Alzheimer disease and normal brain. Brain Res. 919, 115 121.
57. Yin K. J., Cirrito J. R., Yan P. et al. (2006) Matrix metalloproteinases expressed by astrocytes mediate extracellular amyloid-β peptide catabolism. J. Neurosci. 26, 10939 10948.
58. Zhao Z., Xiang Z., Haroutunian V., Buxbaum J. D., Stetka B. Pasinetti G. M. (2007) Insulin degrading enzyme activity selectively decreases in the hippocampal formation of cases at high risk to develop Alzheimer's disease. Neurobiol. Aging 28, 824 830.